諾發集團(01360.HK):可換股債券獲轉換髮行870萬股
格隆匯4月1日丨諾發集團(01360.HK)公佈,有關收購Fortune Selection Limited全部股本事項,公司接獲賣方的換股通知,就本金額800.4萬港元行使第四批可換股債券附帶的換股權。根據換股價每股換股股份0.92港元,合共870萬股換股股份已於2020年4月1日發行予賣方。
緊隨配發及發行換股股份後,公司之已發行股份數目已增加至14.716億股股份,換股股份相當於緊接配發及發行換股股份前公司已發行股本約0.595%以及經配發及發行換股股份擴大後公司已發行股本約0.591%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.